Gamida Cell Ltd. (NASDAQ:GMDA – Get Rating) – Stock analysts at Oppenheimer raised their FY2025 EPS estimates for Gamida Cell in a research report issued on Tuesday, May 10th. Oppenheimer analyst M. Breidenbach now forecasts that the company will post earnings per share of $0.32 for the year, up from their previous estimate of $0.31.
A number of other research analysts also recently weighed in on GMDA. Zacks Investment Research downgraded Gamida Cell from a “buy” rating to a “hold” rating in a report on Monday, April 4th. JMP Securities reaffirmed a “buy” rating and issued a $17.00 price objective on shares of Gamida Cell in a research note on Tuesday, February 1st. HC Wainwright reaffirmed a “buy” rating and issued a $22.00 price objective on shares of Gamida Cell in a research note on Wednesday, March 16th. Finally, Piper Sandler decreased their price objective on Gamida Cell from $13.00 to $6.00 in a research note on Tuesday. One analyst has rated the stock with a hold rating and six have assigned a buy rating to the company. According to MarketBeat, the company presently has an average rating of “Buy” and a consensus target price of $12.39.
Gamida Cell (NASDAQ:GMDA – Get Rating) last released its quarterly earnings data on Tuesday, May 10th. The company reported ($0.34) EPS for the quarter, meeting the consensus estimate of ($0.34). During the same period in the previous year, the firm earned ($0.34) EPS.
Several large investors have recently added to or reduced their stakes in the stock. Stonepine Capital Management LLC grew its holdings in Gamida Cell by 288.8% during the 3rd quarter. Stonepine Capital Management LLC now owns 1,724,201 shares of the company’s stock valued at $6,759,000 after buying an additional 1,280,694 shares in the last quarter. Altshuler Shaham Ltd grew its holdings in Gamida Cell by 93,785.0% during the 3rd quarter. Altshuler Shaham Ltd now owns 499,468 shares of the company’s stock valued at $1,968,000 after buying an additional 498,936 shares in the last quarter. Marshall Wace LLP purchased a new position in Gamida Cell during the 3rd quarter valued at approximately $1,463,000. Renaissance Technologies LLC grew its holdings in Gamida Cell by 153.3% during the 3rd quarter. Renaissance Technologies LLC now owns 531,184 shares of the company’s stock valued at $2,082,000 after buying an additional 321,484 shares in the last quarter. Finally, Highbridge Capital Management LLC grew its holdings in Gamida Cell by 25.4% during the 1st quarter. Highbridge Capital Management LLC now owns 1,000,000 shares of the company’s stock valued at $4,150,000 after buying an additional 202,456 shares in the last quarter. Hedge funds and other institutional investors own 47.12% of the company’s stock.
About Gamida Cell (Get Rating)
Gamida Cell Ltd., a clinical-stage biopharmaceutical company, develops cell therapies to cure blood cancers and serious hematologic diseases. The company's lead product candidate is omidubicel, a cell therapy that has completed Phase III clinical trial in patients with high-risk hematologic malignancies, as well as in Phase I/II clinical trials in patients with severe aplastic anemia.
- Get a free copy of the StockNews.com research report on Gamida Cell (GMDA)
- Is Electronic Arts (NASDAQ: EA) Suddenly A Safe Haven?
- Beyond Meat Stock Value is Improving
- The Travel Sector Is Getting Upgraded
- Carvana Insiders Buy Shares But Maybe You Shouldn’t
- Dutch Bros Gets Scalded By Inflation
Receive News & Ratings for Gamida Cell Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gamida Cell and related companies with MarketBeat.com's FREE daily email newsletter.